Tumor infiltrating CD8+ T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma.

@article{Mella2015TumorIC,
  title={Tumor infiltrating CD8+ T lymphocyte count is independent of tumor TLR9 status in treatment na{\"i}ve triple negative breast cancer and renal cell carcinoma.},
  author={Mikko Mella and Joonas H Kauppila and Peeter Karihtala and Petri Lehenkari and Arja Jukkola-Vuorinen and Ylermi M Soini and P{\"a}ivi Kaarina Auvinen and Markku H Vaarala and Hanna Ronkainen and Saila Kauppila and K M Haapasaari and Katri S. Vuopala and Katri S Selander},
  journal={Oncoimmunology},
  year={2015},
  volume={4 6},
  pages={e1002726}
}
Toll-like receptor 9 (TLR9) is a cellular DNA-receptor of the innate immune system that is widely expressed in cancers. We demonstrated that low tumor TLR9 expression predicts poor disease-specific survival in triple negative breast cancer (TNBC) and renal cell carcinoma (RCC). We hypothesized that this is because TLR9 expression affects tumor immunophenotype. To begin to test this, we compared the number of tumor infiltrating CD8+ T lymphocytes with TLR9 expression in treatment naïve breast… CONTINUE READING
8 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…